Enterprise Value
1.927B
Cash
659.1M
Avg Qtr Burn
-32.13M
Short % of Float
10.84%
Insider Ownership
4.71%
Institutional Own.
99.21%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Birtamimab Details Rare diseases, Amyloid light chain amyloidosis | Phase 3 Data readout | |
NNC6019 (PRX004) Details Rare diseases, Transthyretin amyloidosis | Phase 2/3 Data readout | |
Prasinezumab (alpha-synuclein) Details Neurodegenerative disease, Parkinson's disease | Phase 2 Data readout | |
PRX012 (amyloid beta) Details Alzheimer's disease | Phase 1 Data readout | |
PRX005 (anti-tau) Details Alzheimer's disease | Phase 1 Update |